News

An antibody therapy that ProMIS Neurosciences is developing for Alzheimer’s formed a bond with only the harmful forms of amyloid beta clusters associated with the disease, an indication that it could be an effective treatment, according to a preclinical-trial study. A good sign was that PMN310 didn’t bind to the forms…

A person’s awareness of a cognitive problem, such as memory loss, may be a good indication that he or she is not going to develop Alzheimer’s disease. According to a study conducted by researchers at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada, people who are unaware…

The U.S. Food and Drug Administration (FDA) has placed CT1812 on fast track as a potential treatment of patients with Alzheimer’s disease (AD), the investigative therapy’s developer,  Cognition Therapeutics, has announced. CT1812 is a first-in-class, orally administered small molecule designed to inhibit the binding of amyloid beta oligomers to nerve…

Ionis Pharmaceuticals has started a Phase 1/2 clinical trial to evaluate the Alzheimer’s therapy IONIS-MAPTRx. IONIS-MAPTRx is aimed at reducing the production of tau protein, whose accumulation in the brain is a hallmark of the disease. The trial will evaluate the therapy in patients with mild forms of Alzheimer’s. Therapies targeting…

The Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are  supporting a Johns Hopkins University School of Medicine effort to develop therapies for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Valina Dawson, a neurology professor who is co-director of neuroregeneration and stem cell programs at Johns Hopkins’ Institute for Cell Engineering, will…

Menopause triggers numerous changes in a woman’s body — and, apparently, metabolic changes in the brain as well that puts middle-age women at greater risk of Alzheimer’s disease, a study reports. This finding provides new insights into why women have a higher incidence of this neurological disease, even when a…

The Alzheimer’s disease community has grown accustomed to news of an endless string of failures in clinical trials of potential treatments. In fact, only four such treatments went on to win approval between 1998 and 2014 — addressing symptoms but not altering the relentless course of the disease. PhRMA…

A list of more than 80 compounds in clinical trials for Alzheimer’s disease, released by PhRMA, inevitably brings to mind all those that failed previously. But researchers view the new list as a source of hope, increasingly confident a breakthrough may be among them. Alzheimer’s News Today spoke…

A new test developed by researchers at UC San Francisco and UC San Diego can better predict which cognitively normal adults will develop Alzheimer’s dementia later in life than testing for the well-known genetic variant APOE E4 alone, according to a new study. The study, titled “Polygenic…

The Ontario Neurodegenerative Disease Research Initiative (ONDRI) was designed by Ontario neuroscientists to improve early diagnosis and treatment of neurodegenerative diseases that are inflicted with dementia, such as Alzheimer’s disease. The specifics of this initiative are detailed in an article titled “The Ontario Neurodegenerative Disease Research Initiative (ONDRI),” published…